A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2017
At a glance
- Drugs Lapatinib (Primary) ; Trastuzumab (Primary) ; Carboplatin; Docetaxel
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms TCHL-Phase-II
- 07 Jun 2017 Biomarkers information updated
- 02 Jun 2017 Results (n=78) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 03 Feb 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Sep 2013 to 1 Sep 2014.